交银国际发布研报称，看好康宁杰瑞制药(09966)ADC产品矩阵的巨大全球市场潜力，上调2025-27年收 入预测3-8%，上调目标价至13港元，评级升至"买入"。该行认为，凭借KN026及JSKN003，公司有望实 现在乳腺癌的全线、多亚型覆盖，并拓展其他HER2表达实体瘤的使用，借助差异化布局在HER2赛道拥 有一席之地。 ...

交银国际发布研报称，看好康宁杰瑞制药(09966)ADC产品矩阵的巨大全球市场潜力，上调2025-27年收 入预测3-8%，上调目标价至13港元，评级升至"买入"。该行认为，凭借KN026及JSKN003，公司有望实 现在乳腺癌的全线、多亚型覆盖，并拓展其他HER2表达实体瘤的使用，借助差异化布局在HER2赛道拥 有一席之地。 ...

Core Viewpoint - The release of the first edition of the "Commercial Health Insurance Innovative Drug Directory" in China, which includes 19 drugs, is expected to drive innovation in commercial health insurance products and open up growth opportunities in the health insurance sector [1][2]. Group 1: Innovative Drug Directory - The directory will officially implement on January 1, featuring 19 drugs, including CAR-T for cancer treatment and drugs for rare diseases like neuroblastoma and Gaucher disease, as well as Alzheimer's disease [1]. - The directory emphasizes three characteristics: support for innovation, focus on key areas, and delineation of the boundary between basic medical insurance and commercial insurance [1][2]. Group 2: Growth Opportunities in Health Insurance - Despite a general increase in commercial health insurance premium income, growth has slowed, with premiums not exceeding 1 trillion yuan in the past three years. The innovative drug directory is seen as a means to unlock growth potential [2]. - Data from the Financial Regulatory Authority indicates that health insurance premium income reached 894.3 billion yuan in the first ten months of 2025, a year-on-year increase of 2.3% [2]. Group 3: Industry Transformation - The directory is expected to shift health insurance from homogeneous competition to differentiated innovation, allowing for more precise product design tailored to specific diseases and populations [2][3]. - The establishment of the directory is anticipated to encourage insurance companies to develop specialized insurance products and deepen the "insurance + specialty drug services + health management" ecosystem [2][3]. Group 4: Challenges and Recommendations - Challenges in product pricing, underwriting, and claims processing remain for commercial health insurance, necessitating improvements in data sharing mechanisms between basic medical insurance and commercial insurance [3]. - Industry experts suggest creating a multi-party data sharing platform to support precise pricing and exploring mechanisms like reinsurance and government risk-sharing to mitigate risks [3].

Core Insights - The report from CMB International indicates a leading rating for the mainland pharmaceutical industry, following the National Healthcare Security Administration's announcement of the results from the 2025 Innovative Drug High-Quality Development Conference [1] Group 1: Industry Developments - The recent negotiations for the medical insurance and commercial insurance innovative drug catalog have resulted in many innovative pharmaceutical companies covered by CMB International having products newly included or successfully renewed in the insurance coverage [1] - Companies such as Heng Rui Medicine (600276), Innovent Biologics (01801), CanSino Biologics (09926), and China National Pharmaceutical Group (01177) have more than five products that received new coverage or new indications [1] Group 2: Market Outlook - The inclusion of more new drugs in the catalog is expected to enhance clinical medication levels and improve the overall R&D return rates in the innovative drug industry [1] - The introduction of commercial insurance funds is anticipated to provide significant incremental funding for innovative drug payments, paving the way for a diversified payment system alongside basic medical insurance [1] Group 3: Future Growth Potential - CMB International is optimistic about the sales growth potential of newly included products/indications in 2026, particularly for potential blockbuster products from companies like CanSino Biologics [1] - The report emphasizes the importance of monitoring the actual execution and payment situations of the first batch of commercial insurance catalog, as well as the dynamic adjustments in the list and pricing, and the long-term development opportunities arising from real-world data accumulation [1]

Core Viewpoint - The report from CMB International indicates that global economic resilience in 2025 is expected to exceed initial forecasts, with the AI technology cycle continuing and policies remaining consistent [1] Economic Outlook - The groundwork laid in 2025 is anticipated to facilitate advancements in 2026, supported by ongoing monetary policy easing, proactive fiscal measures, and strategic industrial policies [1] - The external environment is expected to return to order, enhancing certainty and increasing risk appetite, leading to a shift in asset allocation logic towards a balanced approach [1] Hong Kong Stock Market - CMB International projects promising earnings for Hong Kong stocks, with a continuation of a slow bull market [1] - Valuations are deemed reasonable, offering significant cost-effectiveness; the liquidity environment is improving with inflows from southbound and overseas funds [1] - Structural highlights of the Chinese economy include advancements in AI technology, a reduction in excessive competition, and a recovery in domestic demand, which are expected to start reflecting in earnings [1]

Core Insights - Longhua District announced the establishment of a significant industrial fund cluster, including a city-level low-altitude economy industry fund, Pre-REITs fund, and two AIC funds, with a total of 100 billion yuan in comprehensive credit facilities [2][3] Group 1: Fund Establishment and Objectives - The newly launched industrial fund cluster aims to enhance financial connections and support advanced manufacturing, focusing on the "20+8" industrial clusters and the "1+2+3" industrial system in Longhua, particularly in digital economy, new energy, high-end medical devices, integrated circuits, and artificial intelligence [3] - The two AIC funds, each with a total scale of 2 billion yuan, are designed to facilitate collaboration between local capital and industry projects, addressing the last mile of funding [3][4] Group 2: Financial Support and Growth Metrics - Longhua District has provided credit support to over 31,000 enterprises, totaling 160 billion yuan, and aims to enhance financial support for specialized and high-growth enterprises [6][7] - The advanced manufacturing sector in Longhua has shown robust growth, with industrial added value increasing by 5.5% year-on-year, and significant production increases in high-tech products such as industrial robots (26.9%), integrated circuits (33.6%), and civilian drones (58.3%) [6][7] Group 3: Future Outlook and Strategic Focus - Longhua District plans to continue deepening the integration of industry and finance, leveraging digital empowerment to ensure that financial resources are effectively allocated to support the growth of enterprises at all stages [7]

Group 1 - The global economy is expected to show resilience beyond initial forecasts for 2025, with the AI technology cycle continuing and policies remaining consistent [1] - By 2026, the macroeconomic environment is anticipated to return to an orderly state, with economic growth exhibiting a degree of resilience and interest rates likely to remain at restrictive levels [1] - The core logic of asset allocation is shifting towards a balance between offensive and defensive strategies in an environment characterized by high growth resilience, inflation, and interest rates [1] Group 2 - Hong Kong stocks are expected to maintain profitability, with a "slow bull" market continuing; valuations are in a reasonable range, offering strong cost-effectiveness [2] - The liquidity environment is improving, with southbound and overseas capital returning; structural highlights of the Chinese economy, such as AI technology and domestic demand recovery, are expected to start reflecting in profitability [2] - In the US stock market, the "bubble" is difficult to disprove in the short term, and a style shift is anticipated; tech giants benefiting from the AI revolution and capital expenditure expansion still have valuation support due to strong earnings growth and technological barriers, but caution is advised regarding investment slowdown and credit risks [2] - The yield curve for US Treasury bonds is expected to remain in a "hard to lower" pattern, with long-term rates under pressure due to inflation, fiscal, and policy uncertainties, leading to a potential steepening of the yield curve [2]

Group 1 - The core viewpoint of the report is that the company GCL-Poly Energy (03800) has a significant profit advantage in granular silicon, with low electricity consumption aligning with policy directions, and the industry's "anti-involution" is driving a substantial increase in polysilicon prices, with potential further price increases if capacity storage is realized, setting a target price of HKD 1.54 [1] Group 2 - The company is rated as a leader in the domestic renewable energy and public utility sector, with expectations for a historical high in total installed capacity for the year despite a moderate peak season in the first half of 2025 due to policy-driven installations [1] - For 2026, the company anticipates that domestic photovoltaic installations may continue to maintain a high level of 280 GW, while wind power installations are expected to grow by approximately 11% year-on-year to reach 110 GW, supported by a robust bidding volume [1] - The company's preferred order of sub-industries covered is: polysilicon > inverters/storage > operators > photovoltaic glass > battery cells [1]

Core Viewpoint - The report from CMB International expresses optimism about GCL-Poly Energy (03800) due to its significant profitability in granular silicon, low energy consumption aligning with policy directions, and the industry's "anti-involution" leading to a surge in polysilicon prices, with a target price set at HKD 1.54 [1] Industry Summary - The report maintains a leading rating for the domestic new energy and public utility sector, predicting a historical high in total installed capacity for the year despite a moderate peak season for wind and solar installations in the first half of 2025 driven by policy incentives [1] - For 2026, the expectation is that domestic photovoltaic installations will continue to remain at a high level of 280 GW, while wind power installations are projected to grow by approximately 11% year-on-year to reach 110 GW, supported by robust bidding volumes in the past [1] - The preferred order of sub-industries covered by the report is: polysilicon > inverters/storage > operators > photovoltaic glass > battery cells [1]

智通财经APP获悉，交银国际发布研报称，2026年乘用车行业将步入高位整固期，预计全年乘用车零售 销量同比增0.3%至2445万辆，新能源渗透率突破60%。出口方面，预计2026年海外总销量达750-800万 辆。推荐关注具备海外产能与垂直整合优势标的，如比亚迪股份(01211)、吉利汽车(00175)，在Robotaxi 与具身智能具延展性的小鹏汽车-W(09868)。零配件则看好禾赛-W(02525)。 随着机器人售价下探，该行预计2026年C端人形机器人商业化更加顺畅。经过年底阶段性的波动后， 2026年板块有望进入整固及理性回归阶段。重点关注特斯拉(TSLA.US)Optimus量产订单与Gen3样机发 布等节点，以及国产整机厂供应链订单的落实。重卡方面，该行认为，受惠于政策红利释放及新能源渗 透加速，预计2026年内地重卡销量(含出口)同比增5%至约110万辆，看好中国重汽(03808)、潍柴动力 (02338)。锂电方面，该行表示储能需求强劲，产业链盈利改善预期增强，预计明年全球锂电池总需求 同比增约22%，建议关注有成本及技术优势，如宁德时代(03750)。 ...